Last reviewed · How we verify
BTA-C585 oral capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BTA-C585 oral capsules (BTA-C585 oral capsules) — Biota Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BTA-C585 oral capsules TARGET | BTA-C585 oral capsules | Biota Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BTA-C585 oral capsules CI watch — RSS
- BTA-C585 oral capsules CI watch — Atom
- BTA-C585 oral capsules CI watch — JSON
- BTA-C585 oral capsules alone — RSS
Cite this brief
Drug Landscape (2026). BTA-C585 oral capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/bta-c585-oral-capsules. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab